Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% over the past four weeks, the stock looks well positioned for a trend ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...